A Phase 1 Study of Neoadjuvant Chemotherapy, Followed by Concurrent Chemoradiation With Gemcitabine, Sorafenib, and Vorinostat in Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Sorafenib (Primary) ; Vorinostat (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 18 Oct 2017 Planned End Date changed from 31 Jul 2018 to 1 May 2021.
- 18 Oct 2017 Planned primary completion date changed from 31 Jul 2018 to 1 May 2019.
- 10 Jun 2017 Biomarkers information updated